Safety and efficacy of antiseptic cleansing to reduce vertical transmission of multi-drug resistant pathogens to neonates (NeoVT-AMR)
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Importance
Neonatal sepsis causes significant mortality. Antiseptic application to the perineum and vagina of labouring women or to neonatal skin could reduce neonatal pathogenic bacterial colonisation, lowering sepsis risk.
Objective
This study aimed to identify a safe, efficacious antiseptic regimen for a future effectiveness trial.
Design
Randomised controlled trial conducted between March 2022–March 2023. Laboratory staff (who assessed the primary outcome), were blinded to allocation.
Setting
The trial was conducted at Zomba Central Hospital, Malawi on the antenatal and labour wards (maternal stratum) and the neonatal and postnatal wards (neonatal stratum).
Participants
149 women in labour and 147 neonates participated.
Interventions
Participants were individually randomised in an unblinded factorial design to antiseptic (chlorhexidine 1% [CHG1%], chlorhexidine 2% [CHG2%], octenidine 0.1%/phenoxyethanol
2% [OCT]) once or multiple times (maternal: ≤6 four-hourly applications; neonatal: ≤3 24- hourly applications postnatally) or to standard of care (SOC).
Main Outcomes and Measures
The primary outcome was change in total vaginal or neonatal skin bacterial load.
Secondary outcomes in both strata assessed safety by skin condition score, serious adverse events and temperature (neonatal strata only). Additionally, bacterial load of the neonates born to women in the maternal stratum was assessed.
Results
Mean baseline maternal vaginal bacterial load was 6.3 log 10 CFU (log 10 colony forming units (log 10 CFU), SD=2.0), decreasing to 1.5 (SD=2.0) for CHG1% at 4hrs and 5.7 (SD=1.8) for SOC. CHG1% was more efficacious than OCT (absolute effect size=1.7 log 10 CFU, 95%CI[0.9,2.5], p<0.001) and SOC (effect size 3.5, 95%CI [2.4,4.5], p<0.001). There was no difference in efficacy between CHG1% and CHG2% or between application frequencies.
Mean baseline neonatal bacterial load was 4.3 log 10 CFU (SD=2.9), rising to 5.5 (SD=2.7) for CHG1% and 7.4 (SD=2.4) for SOC at 24 hours. CHG1% showed greater efficacy than SOC (effect size=1.2, 95%CI [0.2,2.3], p=0.023), with no difference between antiseptics. Multiple applications showed increasing benefits over time.
No safety concerns were observed.
Conclusion and Relevance
CHG1% was efficacious in both strata, with effect sizes higher in the maternal stratum. This suggests chlorhexidine cleanses could be incorporated into future multimodal infection prevention intervention trials.
Trial registration
NeoVT-AMR is registered on the ISRCTN registry ( ISRCTN78026255 ), registration date 26th May 2022. Protocol and statistical analysis plan available at: https://doi.org/10.1186/ISRCTN78026255 .
Key points
Question: is antiseptic application in labouring women and neonates safe and efficacious at reducing bacterial load?
Findings: this randomised clinical trial included 149 women in labour and 147 neonates. 1% chlorhexidine was efficacious in reducing bacterial load in both strata, with effect sizes higher in the maternal stratum. No safety concerns were observed.
Meaning: chlorhexidine cleanses could be incorporated into multimodal infection prevention intervention trials in neonates and labouring women.
